TrialBritish journal of clinical pharmacology2020

AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.

Hiroyuki Fukase et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.